Literature DB >> 9366575

Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Y Imai1, W H Busby, C E Smith, J B Clarke, A J Garmong, G D Horwitz, C Rees, D R Clemmons.   

Abstract

IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139-->Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366575      PMCID: PMC508461          DOI: 10.1172/JCI119803

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.

Authors:  T Arai; J Clarke; A Parker; W Busby; T Nam; D R Clemmons
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

2.  Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells.

Authors:  C Duan; S B Hawes; T Prevette; D R Clemmons
Journal:  J Biol Chem       Date:  1996-02-23       Impact factor: 5.157

3.  Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix.

Authors:  T Arai; W Busby; D R Clemmons
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

4.  Variables controlling somatomedin production by cultured human fibroblasts.

Authors:  D R Clemmons; D S Shaw
Journal:  J Cell Physiol       Date:  1983-05       Impact factor: 6.384

5.  High-sensitivity sequencing with a gas-phase sequenator.

Authors:  M W Hunkapiller; R M Hewick; W J Dreyer; L E Hood
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta.

Authors:  G L King; A D Goodman; S Buzney; A Moses; C R Kahn
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

7.  Impaired arterial neointima formation in mice with disruption of the plasminogen gene.

Authors:  P Carmeliet; L Moons; V Ploplis; E Plow; D Collen
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

8.  Exposure to platelet-derived growth factor modulates the porcine aortic smooth muscle cell response to somatomedin-C.

Authors:  D R Clemmons
Journal:  Endocrinology       Date:  1985-07       Impact factor: 4.736

9.  Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II.

Authors:  A Gockerman; T Prevette; J I Jones; D R Clemmons
Journal:  Endocrinology       Date:  1995-10       Impact factor: 4.736

10.  The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers.

Authors:  R Ross
Journal:  J Cell Biol       Date:  1971-07       Impact factor: 10.539

View more
  18 in total

Review 1.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

Review 2.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 3.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

4.  Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Authors:  Geneviève Oligny-Longpré; Maithé Corbani; Joris Zhou; Mireille Hogue; Gilles Guillon; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

Review 5.  The role of insulin-like growth factor binding proteins in development.

Authors:  J M Pell; D A M Salih; L J Cobb; G Tripathi; A Drozd
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

6.  Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta.

Authors:  Tsuneo Kobayashi; Akihito Kaneda; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  The association between integrin-associated protein and SHPS-1 regulates insulin-like growth factor-I receptor signaling in vascular smooth muscle cells.

Authors:  Laura A Maile; Jane Badley-Clarke; David R Clemmons
Journal:  Mol Biol Cell       Date:  2003-05-29       Impact factor: 4.138

8.  Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I.

Authors:  A Parker; C Rees; J Clarke; W H Busby; D R Clemmons
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

9.  Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis.

Authors:  Lisbeth S Laursen; Michael T Overgaard; Claus G Nielsen; Henning B Boldt; Kathrin H Hopmann; Cheryl A Conover; Lars Sottrup-Jensen; Linda C Giudice; Claus Oxvig
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

10.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.